In hematologic malignancies with activating JAK mutations, JAK inhibitors have proved clinically useful, however, they target upstream of STAT5 and may be ineffective in PTCL driven by activating STAT5 mutations [15, 36, 37]. This evidence concerns the gene STAT5A and mature T-cell and NK-cell non-Hodgkin lymphoma.